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Abstract
Although some studies described the characteristics of colon cancer stem cells (CSCs) and the role of endothelial progenitor
cells (EPCs) in neovascularization, it is still controversial whether an interaction exists or not between CSCs and EPCs. In the
present study, HCT116 and HT29 sphere models, which are known to be the cells enriching CSCs, were established to
investigate the roles of this interaction in development and metastasis of colon cancer. Compared with their parental
counterparts, spheroid cells demonstrated higher capacity of invasion, higher tumorigenic and metastatic potential. Then
the in vitro and in vivo relationship between CSCs and EPCs were studied by using capillary tube formation assay and
xenograft models. Our results showed that spheroid cells could promote the proliferation, migration and tube formation of
EPCs through secretion of vascular endothelial growth factor (VEGF). Meanwhile, the EPCs could increase tumorigenic
capacity of spheroid cells through angiogenesis. Furthermore, higher microvessel density was detected in the area enriching
cancer stem cells in human colon cancer tissue. Our findings indicate that spheroid cells possess the characteristics of cancer
stem cells, and the coaction of CSCs and EPCs may play an important role in the development of colon cancer.
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Introduction
Colorectal cancer is the third leading cause of cancer deaths
worldwide, and the 5-year relative survival rate is only 53.8–65.2%
despite diagnostic and therapeutic advances [1,2]. Tumor
recurrence and metastasis are two critical survival-influencing
factors of colorectal cancer.
Recently, increasing evidence suggests that tumor initiation and
metastases are dependent on a small sub-population of tumor cells
termed cancer stem cells (CSCs) bearing infinite self-renewal
potential and the capacity to differentiate into diverse populations
comprising a tumor [3]. According to this model, cancer stem cells
were found to sustain carcinogenesis, metastasis, and recurrence of
colorectal cancer.
The existence of cancer stem cells was first proven in the context
of acute myeloid leukemia [4]. This principle was further extended
to some solid tumors, including colon cancer, breast cancer, brain
tumors, and lung cancer [5,6,7,8,9,10]. Cell sorting of a sub-
population on the basis of cell surface markers and confirmation of
their tumor-initiating activity in xenograft transplantation assays
are commonly used procedures for isolation and identification of
CSCs from tumor tissues or cell lines [11]. Although CD133,
CD44, EpCAM were used extensively as cell surface markers for
colon cancer stem cells, there were still doubts on these cell surface
markers [12,13]. Side population (SP) cells isolation were once
used to enrich the cancer stem cells. But several studies showed
evidence against an association between the SP cells and cancer
stem cells [14,15,16,17]. Recently, increasing researches have
reported that the non-adherent, three-dimensional (3D) tumor
spheres under serum-free conditions could efficiently enrich cancer
stem cells [18,19,20] in vitro. Therefore, this method was applied to
enrich colon cancer stem cells in the present study.
Endothelial progenitor cells (EPCs), a minor subpopulation of
the mononuclear cell fraction in peripheral blood, originate mainly
from the bone marrow-derived cells with the ability to differentiate
into mature endothelial cells [21,22]. EPCs leave the bone marrow
and recruit to sites requiring vascular repair following gradients of
growth factors and cytokines that are released into the circulation
by injured tissues or tumors, and then contribute to blood vessel
formation [23,24]. Recent evidences demonstrated that circulating
EPCs play an important role in tumor neovascularization, tumor
growth, and metastasis [25,26,27,28,29].
Although the contribution of EPCs to tumor neovascularization
has been demonstrated in several types of cancer, the interaction
between EPCs and colon cancer stem cells have not been reported.
The aim of this study was to determine the bionomics of colon
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growth and metastasis of colon cancer.
Materials and Methods
Ethics Statement
All experiments involving human participants (including collec-
tion of human umbilical cord blood and colon cancer samples)
have been approved by the Medical Research Ethics Committee
of Sun Yat-sen University, and conducted according to the
principles expressed in the Declaration of Helsinki. All participants
involved in the study signed the informed consent forms and all
animal experiments were conducted according to relevant national
and international guidelines. And this project was approved by the
Medical Research Animal Ethics Committee of Sun Yat-sen
University.
Cell Culture
HCT116 (ATCC, CCL-247) and HT29 (ATCC, HTB-38)
colon cancer cell lines were maintained in DMEM/F12 supple-
mented with 10% FBS, 200 U/ml penicillin, 200 mg/ml strepto-
mycin. Tumorsphere media (also called as serum free medium,
SFM) was composed of DMEM/F12 media supplemented with
16B27 (Invitrogen), EGF (20 ng/ml, Peprotech), bFGF (10 ng/
ml, Peprotech), routine insulin (5 mg/ml, Invitrogen), 200 U/ml
penicillin, and 200 mg/ml streptomycin. For 3D suspension
culture, HCT116 and HT29 cells grown in two dimensional
monolayer were digested with trypsin, resuspended, and then
seeded at a density of 2610
6 cells in SFM in 100 mm ultra-low
attachment dishes (Corning) at 37uC in a humidified 5% CO2 ?
95% air atmosphere.
Detection of CD133 Expression by Flow Cytometry
The cells derived from monolayer cultures and suspension
spheres on day 7 after primary culture were detected for the
expression of CD133. The cells were washed twice in cold PBS,
and subsequently cell suspensions were incubated at 4uC with
1:10 FITC-conjugated mouse monoclonal antihuman CD133 Ab
(Miltenyi biotec) for 45 minutes in the dark. After incubation, the
cells were washed twice in cold PBS with 1% BSA and
resuspended in 400 ml cold PBS with 1% BSA for flow cytometry
analysis within 1 hour.
Self-renew and Multi-differentiation Assay
Spheroid cells were dissociated into single cells and plated in 6-
well plates at 100 cells per well in 2 ml SFM. To evaluate the self-
renew capacity of spheroid cells, cell immunofluorescence staining
of Lgr5 and CK20 were performed after 7 days’ culturing. Cell
differentiation was induced by culturing in DMEM/F12 supple-
mented with 10% FBS in common flasks. Four weeks later, the
same cell immunofluorescence staining was performed, and the
expression of CD133 was determined by FCM as described
before.
Cell Proliferation and Colony Formation Assay
Single-cell suspensions of spheroid and adherent cells were
prepared and seeded at 1610
4 cells per well in 96-well plates, and
cultured in either SFM or serum-containing media for 24 h. Cell
proliferation was performed on day 1, 2, 3, 4, 5, 6, and 7 using
Cell Counting Kit-8 (Dojindo, Japan). The plate colony formation
assay was carried out to determine the colony formation efficacy of
cell in the four groups. Single-cell suspensions were plated at
1610
2 cells per well in 6-well plates, and cultured in serum-
containing media at 37uC in 5% CO2 for 2 weeks. Then the plates
were stained with Giemsa-Wright’s stain. The number of colonies
within each well was counted and photographed. The experiments
were independently performed at least three times.
Homogeneity and Heterogeneity Adhesion Assay
The adhesion ability of cells to ECM was tested using
fibronectin (FN)-coated 96-well plates (Corning). Single-cell
suspensions of spheroid and adherent cells were plated (10
5/well),
and incubated at 37uC for 2 h, then washed with PBS to remove
the non-adhesive cells. Delt OD of 570 nm wavelength was
determined to reflect the FN-adherent cells using Cell Counting
Kit-8 (Dojindo, Japan). The adhesion ability of cells to homoge-
neous cells was tested using monolayer cells-paved 96-well plates.
Spheroid and adherent cells were plated at 10
5 per well, and
incubated at 37uC for 60 min, 90 min, and 120 min. Then the
non-adhesive cells were counted and homotypic adhesive activity
was calculated using the formula: homotypic adhesion (%)=(total
cell number - non-adhesive cells)/total cells6100%.
Migration and Invasion Assays
Migration and invasion assays were performed in 24-well plate
transwell chambers with 8 mm-pore polycarbonate filter inserts
(Corning). A total of 5610
4 or 10
5 dissociated spheroid or
adherent cells were seeded on uncoated or Matrigel-coated inserts
in 100 ml of serum-free medium inserts for migration or invasion
assays respectively. The lower chambers were filled with 0.5 ml of
10% FBS-supplemented DMEM/F12 medium. After 24 h and/or
48 h, cells on the upper side of the filter were removed and the
cells on the lower surface of the insert were fixed and stained with
crystal violet. The number of stained cells was counted under a
light microscope. Assays were performed in triplicates.
Western Blot Analysis
The total cell extracts were separated by 10% SDS-polyacryl-
amide gel electrophoresis and transferred to Polyvinylidene
Fluoride Membrane (Millipore) for ICAM-1, CXCR4 and VEGF
detection. The membranes were washed in Tris-buffered saline
with Tween (TBST, composed of 10 mM Tris-HCl, pH 8,
150 mM NaCl, and 0.05% Tween 20), blocked 1 h at room
temperature with 5% nonfat milk in TBST, and then probed 1 h
at room temperature with anti-ICAM-1 (Santa Cruz Biotechnol-
ogies), anti-CXCR4 (Abcam), anti-VEGF (BD Pharmingen) and
anti-GAPDH (Peprotech). After incubation with horseradish
peroxide-conjugated secondary antibody, immunoreactive pro-
teins were detected by ECL detection system (Millipore). Protein
concentrations were determined by using the BCA protein assay
kit (ThermoScientific Biosciences).
Isolation and Assessment of EPCs
Mononuclear cells were isolated by density gradient centrifu-
gation from human umbilical cord blood and cultured in
fibronectin-coated flask using M199 supplemented with 20%
FBS and 1% extracts of mouse cerebral tissue. EPCs were purified
basing on different adherence rate, and non-adherent cells within
24 h were transferred to another fibronectin-coated flask. After 14
days’ culturing, EPCs were incubated with PE-CD133, FITC-
CD34, PE-VEGFR2 or isotype-matched IgG controls and
identified by flow cytometry as described before.
Cell Proliferation and Migration of EPCs
Single-cell suspension of EPCs was seeded at 2610
4 cells per
well in 96-well plates, and cultured in M199 containing 0, 20%,
and 40% supernatant of spheroid or adherent cells. Cell
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Cell Counting Kit-8 (Dojindo, Japan). Migration assays were
performed to evaluate recruitment of EPCs by spheroid or
adherent cells. Single-cell suspension of EPCs was inoculated at
5610
4 cells per well on inserts in 100 ml of serum-free medium.
The lower chambers were filled with 0.5 ml of DMEM/F12
containing 40% supernatant of spheroid or adherent cells. After
24 h, migrated cells were counted as describe before. Assays were
performed in triplicates.
In vitro Capillary Tube Formation
Supernatants of HT29, HT29 Sphere, HCT116 and HCT116
Sphere were added to 24-well plates (Corning Inc) coated with
growth factor reduced Matrigel (BD Biosciences). To illustrate if
tube formation capacity of EPCs can be influenced by blocking
VEGF, bevacizumab (avastin, a VEGF monoclone antibody,
Genentech Inc) was added to supernatant of spheroid cells at a
concentration of 0.25 mg/ml as another two groups [30,31]. Then
a total of 5610
4 EPCs were seeded and incubated at 37uC, 5%
CO2 for 3 to 30 h. After 24 h, capillary tubes were counted in
random fields from each well. Assays were performed in triplicates.
ELISA
To demonstrate the a paracrine effect of cancer stem cells and
confirm the result of VEGF detection from Westerm Blot analysis,
we investigated VEGF secretion by cancer stem cells using a
quantitative method. VEGF concentration in supernatant of
spheroid/adherent cells were determined by ELISA (R&D
Systems) according to the protocol provided by the manufacturer.
And also, the experiment was performed three times.
In vivo Tumorigenesis
To determine whether spheroid cells are more tumorigenic than
their adherent counterparts in vivo and whether EPCs promote
their tumorigenic capacity by increasing tumor angiogenesis, we
carried out tumor development and liver metastasis experiments.
Single cells were resuspended in PBS. And then 100 ml suspensions
containing 2610
6 adherent cells, spheroid cells, or spheroid cells
plus 2610
5 or 2610
4 EPCs (the spheroid cells and EPCs ratio of
10:1 and 100:1) were injected subcutaneously (s.c.) into the flanks
of 4- to 6-week-old male BALB/C-nu mouse, obtained from the
Jackson Laboratory. Subcutaneous tumor diameters were mea-
sured with a digital caliper every two or three days, and tumor
volume in mm
3 was calculated using the formula: Volume =
width
26length60.52. Then 3 or 4 weeks later, the mice were
killed and frozen tissue sections (6 mm) of subcutaneous tumors
were made for immunofluorescent staining to observe the
angiogenesis in each group. Here we use a non-specific polyclonal
CD31 antibody to detect the neovascularization of the subcuta-
neous tumor, and another monoclonal human-specific CD31
antibody for the EPCs contribution to angiogoiesis.
In vivo Liver Metastasis
Liver metastatic model was used to determine the metastatic
potential of spheroid cells and whether EPCs promote this
capacity by increasing tumor angiogenesis. Hepatic metastases
were produced by intrasplenic injection of 4610
6 adherent cells,
spheroid cells, or speroid cells plus 4610
5 or 2610
4 EPCs (the
ratio of 10:1 or 100:1), and then splenectomy was performed
10 min after intrasplenic injection to avoid splend metastasis. The
overall health condition was recorded in detail once a day. Liver
metastasis foci were examined and measured. And tissue section
was made for HE staining to confirm the pathological source.
Clinical Evidence Obtained by Immunofluorescent
Staining
Frozen sections (6 mm) of colon cancer tissue and normal colon
mucosa (n=15, from the same patient) were fixed with 4%
paraformaldehyde/PBS, treated with microwave for 10 min for
immunofluorescent staining. The anti-CD31 Ab (Fisher Scientific),
the anti-CD133 Ab (Abcam), the anti-Lgr5 Ab (Abcam), and the
anti-CK20 Ab (Santa Cruz Biotechnologies) were used according
to the manufacturer’s protocol. Counterstaining of nuclei with
DAPI (Invitrogen) was also performed. The sections were
incubated with according secondary DeLight448- or 555-conju-
gated anti-mouse or rabbit Ab (Abcam) for 1 h at room
temperature or overnight at 4uC. Images were captured with a
Zeiss confocal microscope (LSM-710). Here, throughout this
manuscript, data from at least three independent experiments
have been analyzed to verify reproducibility of results.
Statistical Analysis
Statistical significance was determined by one-way ANOVA
followed by Bonferroni post-hoc test for multiple comparisons or
Student’s t-test. For all tests, P,0.05 or ,0.01 was considered
significant or highly significant statistically.
Results
Generation and Characterization of Colonospheres
Both HCT116 and HT29 colon cancer cells grew in large
round, unattached floating spheroid colonies (termed colono-
spheres) when they were cultured in serum free medium
supplemented with 16B27, 20 ng/ml EGF, 10 ng/ml bFGF
(Figure 1). The frequency of sphere-forming cells was determined
by performing an extreme limiting dilution analysis (ELDA) for
parental and colonospheres-derived HCT-116 cells. The frequen-
cy to form spheres was found to be 5.5 fold higher for cells derived
from colonospheres than those from the parental cell lines.
The spheroid cells showed higher levels of CD133 and Lgr5
(known as colon CSC markers), but lower levels of differentiated
epithelial cell marker CK20 than the corresponding parental cells.
The proportion of the CD133 positive cells was found to be less
than 1% in parental cell lines, but more than 80% observed in
spheroid cells (Figure 2). When the colonospheres were subjected
to immunofluorescence staining for Lgr5, obvious Lgr5 staining
was observed on the the surface of most spheroid cells indicating
the presence of CSCs in colonosphere (Figure 2). When the
spheroid cells were cultured in 10% FBS containing medium, they
attached to the plastic, gradually migrated from colon spheres and
changed into adherent cells morphologically. Flow cytometry and
immunofluorescence examination showed down-regulated CD133
and Lgr5 expression with up-regulated CK20 after 4 weeks’
culturing (Figure 2). The results suggest that CSCs were efficiently
enriched in spheroid cells, and they have the capacity of self-renew
and multi-differentiation.
Spheroid Cells Display Higher Capacity of Proliferation
and Clone Formation
We further determined whether the spheroid cells have capacity
of higher cell proliferation using CCK-8 assay. The proliferations
of spheroid cells were higher than that of their parental
counterpart after a period of adaptation to serum containing
medium (Figure 3A and 3B). And the capacity of colony formation
in spheroid cells groups was higher than that of their parental
counterpart (Figure 3C and 3D).
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vitro Migratory/invasive Capacity
To investigate the malignant profile of spheroid cells, we
conducted in vitro assays to evaluate the adhesion and migratory/
invasive capacity of spheroid cells in comparison with their
adherent counterparts. The results of cell adhesion assay
demonstrated that spheroid cells have lower capacities of both
adhesion to FN (one of the key ECM components) and adhesion to
their homogeneous neighbors, as compared with their parental
cells (Figure 4A and 4B). Then CXCR4 and ICAM-1 expression
in HCT116/HT29 spheroid cells was examined and compared
with their parental cells. The ICAM-1 level was modestly down-
regulated, while CXCR4 expression was up-regulated in
HCT116/HT29 spheroid cells when compared with HCT116/
HT29 monolayer cells respectively (Figure 4C).
Using Transwell migration chambers, we found that spheroid
cells display a significant increase in cell motility. Compared with
HCT116/HT29 adherent cells, HCT116/HT29 spheroid cells
showed a 3.8-fold (p,0.01) and 4-fold (p,0.001) increase in
chemotactic potential at 24 h, respectively (Figure 4D). These cells
also demonstrated higher capacity to invade Matrigel-coated
inserts in Transwell migration chambers. More HCT116/HT29
spheroid cells were obviously observed to invade Matrigel as
compared with corresponding adherent cells (p,0.001 and
p,0.05, respectively) (Figure 4E). These results indicate that
spheroid cells are endowed with lower adhesion, but higher
migratory/invasive capacity, a functional phenotype associated
with tumor aggressiveness.
Spheroid Cells Promotes Proliferation, Migration and
Tube Formation of EPCs Through Up-regulating VEGF
Expression
Purified EPCs were obtained from human umbilical cord blood.
Flow cytometry analysis showed that EPCs in later stage displayed
a certain expression of CD34 and CD133, but high level
expression of VEGFR2 (Figure 5A–5C). Cell proliferation and
migration of EPCs induced by supernatants of spheroid cells were
higher than their counterparts (Figure 5D and 5E). The tube
formation assay showed that more tubes formed in spheroid cells
group than adherent cells group. Additionally, when 0.25 mg/ml
bevacizumab (avastin, a VEGF monoclonal antibody) was added
in supernatant of spheroid cells, the tube formation capacity of
EPCs was suppressed (Figure 6A). Then the VEGF secretions in
supernatants of spheroid/adherent cells were detected using
ELISA. The results showed that concentration of VEGF in
supernatant of adherent cells was lower than spheroid cells
(Figure 6B). The expression of spheroid/adherent cells were
evaluated by Western blot (Figure 6C). The results illustrated that
VEGF may play an important role in the effect of spheroid cells on
EPCs, which suggested that spheroid cells may promote angio-
genesis of EPCs through up- regulating VEGF expression.
Spheroid Cells Possess Higher Tumorigenic and
Metastatic Potential in vivo and EPCs Can Increase these
Capacities
The spheroid cells showed significantly higher tumorigencity
than adherent cells (Figure 7A, 7B and 7E). When 2610
6 cells
were inoculated into nude mice, all mice developed tumors.
Transplanted tumors were confirmed as colon cancers with
hematoxylin-eosin staining. And the volumes of subcutaneous
tumor in spheroid cells groups were significantly higher than that
of adherent cells groups. Moreover, the volumes of subcutaneous
tumor in spheroid cells plus 1/10 EPCs groups were higher than
that of pure spheroid cells groups (Figure 7C, 7D and 7F). But no
significant difference was found between pure spheroid cells and
spheroid cells plus 1/100 EPCs (data not shown). Then blood
vessels density in tumor tissues were evaluated using CD31
immunofluorescence staining. More blood vessels were found in
Figure 1. Morphological change of adherent, spheres, and differentiated HCT-116 and HT29. Both HCT116 and HT29 can form large
round, unattached floating colonsphere of 50–100 mm when cultured in SFM. When spheroid cells were cultured in 10% FBS containing medium, the
floating spheroid cells attached to the plastic, gradually migrated from colonspheres and transformed to adherent cells.
doi:10.1371/journal.pone.0039069.g001
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even more angiogenesis in tumor tissue was observed in the
combined group of HCT116 sphere plus 1/10 EPCs (Figure 7G–
7J). And the MVD were counted according to the non-specific
polyclonal CD31 antibody. In order to determine the EPCs
contribution, we performed IF staining using human-specific
monoclonal CD31 antibody. The result showed more blood
vessels in the combined group of HCT116 sphere plus EPCs than
pure spheroid cells (Figure 7K–L).
As the liver metastasis was concerned, four mice (4/5)
developed liver metastasis in spheroid cells group, but only one
mouse (1/5) did in adherent group. Metastatic tumors were also
confirmed as colon cancers with hematoxylin-eosin staining (figure
not shown). The result of liver metastatic foci counting showed the
similar results (Figure 7M). The overall conditions of the mice in
spheroid cells group are worse than those in adherent cells group,
and some of them developed ascites and severe emaciation. And
there were no significant difference between spheroid cells plus
EPCs (with ratio of 10:1 and 100:1) groups and spheroid cells
groups (data not shown).
Clinical Evidence for Cancer Stem Cells Promote
Angiogenesis in Human Colon Cancers
To support our experimental findings, we examined whether
colon cancer stem cells promote angiogenesis within human colon
cancers, and the normal mucosa from the same patient as control.
The immunofluorescent staining of CD133/Lgr5 (colon cancer
stem cell marker) and blood vessel EC marker CD31 were
performed. As we all know, there are more microvessels in cancer
tissue than normal tissue. In addition to this, we found that higher
microvessel density in the area enriching cancer stem cells in the
fresh specimen of human colon cancer (Figure 8).
Discussion
In the 70s of the last century, Fidler IJ et al. [32] proposed the
concept of tumor heterogeneity, which presume there were
different phenotypes in the tumor tissue. The cancer stem cell
theory was shaped based on this concept. Cancer stem cell is
generally defined as a small sub-population of tumor cells bearing
self-renewal and multi-directional differentiation potential [11].
Up to now, the existence of cancer stem cells has been confirmed
in several solid tumors, including colon cancer. According to this
Figure 2. CD133/CD44, Lgr5, and CK20 expression of adherent, spheres, and differentiated HCT-116 and HT29. CD133 (known as
cancer stem cell marker) expression rises from #1.2% up to 60%–80% when cultured in SFM, but reduced to 5%–10% when the colonsphere
changed back into adherent cells. The same change of Lgr5 (known as crypt stem cell marker) expression can be found while CK20 expression, the
marker of differentiated epithelial cell, showed the adverse change.
doi:10.1371/journal.pone.0039069.g002
Figure 3. Proliferation and clone formation of adherent and spheroid cells of HCT-116 and HT29. (A–B) Proliferation of HCT116 and
HT29 spheroid cells were higher than that of their parental counterparts after a period of adaptation to serum containing medium. (C–D) The capacity
of colony formation in spheroid cells groups was higher than that of their parental counterpart.
doi:10.1371/journal.pone.0039069.g003
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bearing the whole characteristic of malignancy, including infinite
proliferation, invasion and metastasis, relapse and resistance to
therapy.
Nowadays, the extensively used method to isolate or enrich
colon cancer stem cells is cell sorting based on cell surface markers,
such as CD133, Musasai-1, CD44, EpCAM, Lgr5, etc. Ricci-
Vitiani L et al. reported the CD133
+ cells which accounts for
about 2.5% of the tumour cells are tumorgenic cells in colon
cancer [33]. Subcutaneous injection of colon cancer CD133
+ cells
readily reproduced the original tumor in immunodeficient mice,
whereas CD133
2 cells did not develop tumors. However, there
were still many different opinions on these cancer stem cell
markers. For example, Shmelkov SV proposed that CD133
expression is not restricted to stem cells, and both CD133
+ and
CD133
2 metastatic colon cancer cells initiate tumors [12]. Some
researchers reported the dye-effluxing side population cells
expressing ABCG2, an ATP-binding cassette half-transporter,
could be isolated as cancer stem cells [34,35,36]. However, several
studies showed evidence against an association between the SP
population and cancer stem cells. SP cells isolated from MKN28
gastric cancer cells did not produce tumor in a xenograft model
Figure 4. Cell adhesion and migratory/invasive capacity of adherent and spheroid cells. (A–C) Spheroid cells have lower capacities of
both adhesions to FN (A) and to their homogeneous neighbors (B), as compared with their parental cells. The ICAM-1 expression in speroid cells was
modestly down-regulated, while CXCR4 expression was up-regulated as compared to HCT116/HT29 monolayer cells respectively (C). (D and E)
HCT116/HT29 spheroid cells showed a 3.8-fold (p,0.01) and 4-fold (p,0.001) increase in chemotactic potential at 24 h (D). More spheroid cells were
obviously observed to invade Matrigel as compared to their parental counterparts (p,0.001 and p,0.05, respectively, E).
doi:10.1371/journal.pone.0039069.g004
Figure 5. Supernatants of spheroid cells promote proliferation and migration of EPCs. (A-C) EPCs adhere to FN-coated flask after 72 hr
and EPCs clones can be seen after one week (A), and present cobbles-like sign after two weeks (B). EPCs in later stage display a certain expression of
CD34 and CD133, but high level expression of VEGFR2 (C). (D, E) Cell proliferation (D) and migration (E) of EPCs treated by supernatants of spheroid
cells were higher than their counterpart.
doi:10.1371/journal.pone.0039069.g005
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demonstrate equivalent multipotential differentiation capacity and
similar tumorigenicity in xenograft model [38].
In the present study, we obtained tumor spheres from HCT116
and HT29 colon cancer cell lines by culturing these cells in serum-
free medium [39,40]. And the following analysis indicated that
CD133 and Lgr5 expression of these spheroid cells was higher
than their parental counterpart, while CK20 expression was lower
which represents the differentiated endothelial cell. The contra-
dictory phenotypes were detected when the spheroid cells were
induced to differentiate in FBS containing medium. Moreover, the
spheroid cells can form the same spheres, indicating that they have
the self-renew capacity. From these results, we can draw the
conclusion that cancer stem cells were enriched in these spheroid
cells.
In order to take a further insight into the biological behavior of
these spheroid cells, we performed a series of functional
experiments. The results showed that spheroid cells display higher
capacity of proliferation and clone formation, which represent self-
renewal potential, as compared to their adherent counterparts.
And also, spheroid cells demonstrate lower capacities of both
adhesions to FN (one of the key ECM components) and adhesion
to their homogeneous neighbors. That was to say, this kind of cells
are easier to release from the bulk tumor. ICAM-1 is an important
cell surface molecular mediating the intercellular adhesion and its
downregulation can explain the lower homogenic adhesion of
spheroid cells. Our results indicated that spheroid cells have
enhanced in vitro migration and invasion potential. CXC
chemokine receptor 4 (CXCR4) interacts specifically with the
stromal cell-derived factor-1 (SDF-1), which is expressed in
stromal cells, including fibroblasts and endothelial cells [41,42].
Recent studies showed that chemotaxis effect of CXCR4/SDF-1
axis is related with lymph node and liver metastasis of CRC
[43,44,45,46]. And in our study, we found expression of CXCR4
of spheroid cells were upregulated.
The circulating, bone-marrow-derived EPCs contribute to
angiogenesis- mediated pathological neovascularization, and
recent studies have begun to recognize the biological significance
of this contribution, especially to the growth and metastasis of
tumors. Generally speaking, circulating EPCs recruit to sites of
tumors following gradients of growth factors, such as vascular
endothelial growth factor (VEGF), SDF-1 etc, which are released
Figure 6. Supernatants of spheroid cells promote tube formation of EPCs through VEGF up-regulation. (A) Tube formation of EPCs
treated by supernatants of spheroid cells was higher than their counterparts. And tube formation of EPCs was suppressed when we block the
function of VEGF by bevacizumab. (B) The VEGF concentrations in supernatants of spheroid cells were higher than those of adherent cells. (C) Higher
VEGF expression was observed in the spheroid cells compared with their counterparts.
doi:10.1371/journal.pone.0039069.g006
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and SDF-1 in tumors could be enhanced each other. And in the
other hand, VEGF could up-regulate the expression of CXCR4 in
vascular endothelial cell, thus promote the migration of EPCs and
contribute to tumor neovascularization [48]. In our study, we
isolated EPCs, which display a certain expression of CD34 and
CD133, but high level expression of VEGFR2 in its later stage.
And we found that supernatants of spheroid cells can promote
proliferation, migration and tube formation of EPCs by up-
regulating VEGF expression and bevacizumab can suppress the
angiogenesis of EPCs by blocking the function of VEGF (Figure 5,
6). The results of xenograft model indicated that EPCs can
promote the growth of subcutaneous tumor of spheroid cells by
mediating neovascularization (Figure 7). And using the human
specific CD31 antibody, we can detect the blood vessel developed
from EPCs. The results indicated that EPCs may play an
important role in the neovascularization. It can be seen that
VEGF is relevant to the interaction between EPCs and CSCs.
Since the EPCs may be responsible for turning on the ‘‘angiogenic
switch’’, our results indicates a therapeutic strategy can be
employed to keep this switch in the ‘‘off’’ position for colorectal
cancer [47]. That is to say, if we block the interaction between
EPCs and CSC, decreased tumor vascularization and suppressed
tumor progression can be expected. Although no significant
difference were found between spheroid cells plus EPCs groups
and spheroid cells groups in liver metastasis, which may be due to
the short observation period and limited sample size.
Tofurtherconfirmthecorrelationbetweencoloncancerstemcells
and the tumor neovascularization, we then performed immunoflu-
orescenceintumortissues.CD31expressionisassociatedtoCD133
orLgr5expressionincoloncancertissues(Figure8),whichindicates
robustangiogenesisisstimulatedbycancerstemcells.Inrecentyears,
the evidence strongly indicates that CSCs not only promote self-
renewal and tumor initiation, but also induce and stimulate
angiogenesis.Theyseemtobeadeptatinitiatingapotentangiogenic
response by inducing and secreting certain proangiogenic factors,
such as VEGF, which constitute one of the CSC factor subsets
[40,49]. These factors may promote the EPCs migration and
neovascularization. Interestingly, in addition to the close link
between angiogenesis and CSCs [50], certain stem-like cells can
transdifferentiate into endothelial-like cells to form tumor blood
vessels via a process termed vasculogenic mimicry [51,52,53]. This
can be used to explain why human CD31 antigen exists in
subcutaneous tumordeveloped from spheroidcells (Figure 7K).
Figure 7. Spheroid cells possess higher tumorigenic and metastatic potential in vivo and EPCs can increase these capacities. (A–F)
The spheroid cells showed significantly higher tumorigenecity than adherent cells (A, B, E). And the volumes of subcutaneous tumors in spheroid cells
plus EPCs groups were larger than those of spheroid cells groups (C, D, F). (G–J) Microvessel density (MVD) of tumor developed by HCT116 spheroid
cells (H) was higher than that of HCT116 (G). The highest MVD among these groups was found in tumor tissue developed from HCT116 sphere plus 1/
10 EPCs (I, J). And more blood vessel developed from human EPCs in HCT116 sphere plus EPCs group (L) were found than that of pure spheroid cells
group (K). (M) The HCT116 spheroid cells developed more liver metastatic foci than HCT116.
doi:10.1371/journal.pone.0039069.g007
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39069Figure 8. Cancer stem cells promote angiogenesis in human colon cancers. (A) More microvessels in cancer tissue than normal tissue were
observed by immunofluorescent staining of CD133 and CD31 of normal mucosa and colon cancer. And higher MVD were found in the area enriching
CD133
+ cancer stem cells in colon cancer tissue. (B) Higher MVD (CD31
+) were found in the area enriching Lgr5
+ cancer stem cells in colon cancer
tissue.
doi:10.1371/journal.pone.0039069.g008
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39069Taken together, our results demonstrate that HCT116 and
HT29 spheroid-derived cells possess the characteristics of cancer
stem cells, including higher capacity of proliferation and clone
formation, higher migratory and invasive potential, and also
enhanced tumorigenic and metastatic potential. The spheroid cells
could promote the proliferation, migration and tube formation of
EPCs through secretion of VEGF, and simultaneously EPCs could
increase tumorigenic capacity of spheroid cells through angiogen-
esis vice versa. Our findings indicate that the coaction of CSCs
and EPCs may play an important role in the development of colon
cancer.
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